Long Life Novo Nordisk

Long Life Novo Nordisk

05 May 2023

Key Indicators

Index / Fund / Rate Start of Year Last week This Week % change YTD
Lunar BCI WW Flexible Fund 141.43 161.59 160.55 13.52%
JSE ALSI 73 049 78 218 78 133 6.96%
NASDAQ Composite 10 467 12 227 12 235 16.90%
S&P 500 3 840 4 169 4 136 7.71%
Prime Lending Rate 10,50% 11.25% 11.25% 7.14%
USD/ZAR 16,98 18.36 18.41 8.42%
EUR/ZAR 18,44 20.14 20.29 10.01%
Brent Crude ($’barrel) 85,95 80.25 75.27 -12.43%

Source: Iress

Weekly Stocktake with Danyaal

Long Life Novo Nordisk

Over the last few decades, the average life expectancy in developed nations has been increasing. This has been due to a number of factors such as advancements in medical technology, improved public health measures, and a greater focus on preventative care. However, some consequences of people aging, is that they are more likely to develop chronic health conditions such as heart diseases, cancer, and diabetes – all of which require ongoing medical care.

Novo Nordisk, a Lunar Capital holding, is a Danish pharmaceutical company that specialises in the development and manufacturing of treatments for diabetes, obesity, and other chronic diseases. Novo Nordisk, along with Eli Lilly (another Lunar Capital holding) are two of the leading players treating chronic medical-conditions.

Ozempic, a popular treatment developed by Novo Nordisk, was initially used to treat type-2 diabetes. However, it was discovered that Ozempic influences weight loss as well. The medication produces a digestive hormone called glucagon that ultimately reduces appetite, leading to weight loss in patients. In the United States, Ozempic is currently only FDA-approved drug for use in treating type-2 diabetes. However, some physicians may prescribe Ozempic for off-label use, which allows them to prescribe the medication for other conditions, such as treating obesity. Some studies indicate that approximately 40% of people in the USA are obese, providing a large market for drugs such as Ozempic.

Pharmaceutical companies operate in a highly regulated industry with country-specific requirements that can be challenging to navigate. Developing new treatments is a lengthy and costly process with no guarantees of success, but these companies invest heavily in research and development to remain competitive. However, the industry’s public-facing nature means that any negative outcomes or unintended consequences from treatments could result in significant reputational and financial losses. Nonetheless, if pharmaceutical companies can navigate these challenges successfully, they can be compensated well for it.

Connect with us on social media:

LinkedIn: https://bit.ly/413pDnr
Facebook: https://bit.ly/3ScL7Km
Instagram: https://bit.ly/3ICEjCJ

Lunar Capital on Eastwave Radio

Every Tuesday, at 07h45, Sabir chats with Nazia from Eastwave Radio (92.2 fm, live stream on www.eastwave.co.za) on investing and the markets.

Click here to access your account to view statements, obtain tax certificates, add, or make changes to your investments.

Our email address is: [email protected]

Disclosures
Read our full Disclosure statement: https://lunarcapital.co.za/disclosures/
Our Privacy Notice: https://lunarcapital.co.za/privacy-policy/
The Lunar BCI Worldwide Flexible Fund Fact Sheet  can be read here.
This roundup is prepared for the clients of Lunar Capital (Pty) Ltd. This roundup does not constitute financial advice and is generated for information purposes only.
Share article

Latest Posts

Disney – Where is the Magic?
Disney – Where’s the Magic?
How did Disney lose its sparkle, and what are they doing to get it back.
Amazon – Not your everyday Bookseller
Amazon – Not your everyday Bookseller
What characteristics have made Amazon the everything store
Microsoft: On Cloud Nine
Microsoft: On Cloud Nine
ind out how AI has been benefitting Microsoft

Lunar Capital
on Eastwave Radio

Every Wednesday, at 07h45, Sabir chats with Nazia from Eastwave Radio (92.2 fm, live stream on
www.eastwave.co.za) on investing and the markets.

eastwave-radio
Scroll to Top